Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) have been given an average rating of "Moderate Buy" by the fourteen ratings firms that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $24.50.

Several equities research analysts recently weighed in on KURA shares. Wall Street Zen cut shares of Kura Oncology from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Mizuho cut their target price on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, May 19th. Barclays cut their target price on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Wedbush restated an "outperform" rating and set a $36.00 price objective on shares of Kura Oncology in a research note on Friday, June 20th. Finally, JMP Securities reiterated a "market outperform" rating and set a $28.00 target price on shares of Kura Oncology in a research note on Wednesday, June 4th.

Kura Oncology Price Performance

Shares of NASDAQ:KURA traded up $0.11 during trading on Friday, reaching $6.47. The company had a trading volume of 1,349,051 shares, compared to its average volume of 1,289,696. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.07 and a current ratio of 8.07. The firm's fifty day moving average is $6.11 and its 200 day moving average is $6.83. Kura Oncology has a twelve month low of $5.41 and a twelve month high of $21.60. The firm has a market capitalization of $560.11 million, a PE ratio of -3.08 and a beta of 0.40.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analysts' expectations of $39.08 million. On average, equities analysts forecast that Kura Oncology will post -2.44 EPS for the current year.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its stake in Kura Oncology by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 635,494 shares of the company's stock worth $5,535,000 after buying an additional 10,542 shares during the last quarter. Corient Private Wealth LLC purchased a new position in Kura Oncology in the fourth quarter worth approximately $109,000. Thrivent Financial for Lutherans purchased a new position in Kura Oncology in the fourth quarter worth approximately $250,000. Teacher Retirement System of Texas boosted its position in shares of Kura Oncology by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock worth $120,000 after buying an additional 2,285 shares during the period. Finally, Blueshift Asset Management LLC purchased a new position in shares of Kura Oncology during the fourth quarter worth $174,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.